VERA•benzinga•
Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch
Summary
Vera Therapeutics completes enrollment in Phase 3 atacicept trial for IgAN, with interim efficacy results expected this quarter to support 2025 FDA filing.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 9, 2025 by benzinga